Latest Healthcare It News

Synlait Milk Limited has completed the sale of its North Island assets to Abbott for NZ$307 million, significantly reducing its bank debt and refocusing its operations on Canterbury.

Healthscope has paid all rent due through April 2026 for hospitals owned by HealthCo Healthcare & Wellness REIT, while alternative operators submit plans to take over hospital operations.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

Enlitic has landed a US$1.2 million contract to migrate and standardise millions of medical imaging records for Parkland Health, marking its third major US healthcare win this month.

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Enlitic has secured a $250,000 data migration contract with St. Jude Children’s Research Hospital, marking its first foray into paediatric healthcare and opening doors for its AI-powered platform Ensight.

Firebrick Pharma has successfully secured $1.5 million through a strategic placement, positioning itself to accelerate business development and launch new products in key markets.

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.

Nexsen Limited's subsidiary has won a HK$6 million grant to accelerate clinical validation and manufacturing of its rapid Group B Streptococcus diagnostic in Hong Kong, positioning the city as a key Asia-Pacific hub.

Patrys Limited is advancing a proprietary injectable formulation of quetiapine aimed at the large and underserved delirium treatment market, leveraging an accelerated FDA approval pathway and extensive existing safety data.

Blue Star Helium has successfully raised A$10 million through an oversubscribed placement, positioning itself to accelerate production at its Galactica and Pegasus helium projects.